ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Immunogenicity Study to Evaluate Single- or Two-Dose Regimens Of RSV F Vaccine With and Without Aluminum Phosphate or Matrix-M1™ Adjuvants In Clinically-Stable Older Adults

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03026348
Recruitment Status : Active, not recruiting
First Posted : January 20, 2017
Last Update Posted : September 13, 2017
Sponsor:
Information provided by (Responsible Party):
Novavax

January 17, 2017
January 20, 2017
September 13, 2017
January 2017
April 2017   (Final data collection date for primary outcome measure)
  • Neutralizing antibody titers to at least one RSV/A strain [ Time Frame: Day 0, 21, 28 ]
  • Subjects with solicited local and systemic AEs occurring within the 7-day period following dosings on Day 0 and Day 21 and all adverse events, solicited and unsolicited, occurring within the 56-day period of Day 0. [ Time Frame: Day 0 - Day 6, Day 21 - Day 27; Day 0 - Day 56 ]
Same as current
Complete list of historical versions of study NCT03026348 on ClinicalTrials.gov Archive Site
  • Serum concentrations of antibodies competitive with palivizumab (i.e., PCA) for binding to the RSV F protein. [ Time Frame: Day 0, 21, 28, 56, 119, 385 ]
  • Serum IgG antibody concentrations as ELISA units (EUs) specific for the F protein antigen. [ Time Frame: Day 0, 21, 28, 56, 119, 385 ]
  • Counts of IFN-γ spot forming units following in vitro stimulation of Day 0, Day 7, and Day 28 PBMC isolates with RSV F peptides. [ Time Frame: Day 0, 7, 28 ]
  • Counts and proportions of Day 0, Day 7, and Day 28 peripheral blood T cells positive by intracellular staining for IL-2, IFN-γ, or TNF-α production (alone or any combination thereof) following in vitro stimulation with RSV F peptides. [ Time Frame: Day 0, 7, 28 ]
Same as current
Not Provided
Not Provided
 
Safety and Immunogenicity Study to Evaluate Single- or Two-Dose Regimens Of RSV F Vaccine With and Without Aluminum Phosphate or Matrix-M1™ Adjuvants In Clinically-Stable Older Adults
Safety and Immunogenicity Study to Evaluate Single- or Two-Dose Regimens Of RSV F Vaccine With and Without Aluminum Phosphate or Matrix-M1™ Adjuvants In Clinically-Stable Older Adults
This is a randomized, observer-blind, trial in clinically-stable older adults. Up to 300 eligible older adults 60 through 80 years of age will be enrolled at a 1:1 ratio into multiple dose/formulation treatment arms. Safety and immunogenicity data through Day 56 will be used to select a vaccine candidate to potentially evaluate in a Part 2 study. Proportions of subjects in various strata will not be pre-specified and the goal will be to achieve an approximately equal distribution of subjects with these characteristics across the treatment groups. Serology measures consistent with the study outcomes will be reported.
Not Provided
Interventional
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Respiratory Syncytial Viruses
  • Biological: RSV F Vaccine with Aluminum Phosphate Adjuvant
  • Biological: RSV F Vaccine
  • Biological: Matrix-M1 Adjuvant
  • Other: Phosphate Buffer
  • Active Comparator: Treatment Group A
    Day 0 RSV F Vaccine 135µg/0.5mL Day 21 Phosphate Buffer
    Interventions:
    • Biological: RSV F Vaccine
    • Other: Phosphate Buffer
  • Active Comparator: Treatment Group B
    Day 0 Treatment / Formulation 1 Day 21 Phosphate Buffer
    Interventions:
    • Biological: RSV F Vaccine with Aluminum Phosphate Adjuvant
    • Other: Phosphate Buffer
  • Active Comparator: Treatment Group C
    Day 0 Treatment / Formulation 1 Day 21 Treatment / Formulation 1
    Intervention: Biological: RSV F Vaccine with Aluminum Phosphate Adjuvant
  • Active Comparator: Treatment Group D
    Day 0 Treatment / Formulation 2 Day 21 Phosphate Buffer
    Interventions:
    • Biological: RSV F Vaccine with Aluminum Phosphate Adjuvant
    • Other: Phosphate Buffer
  • Active Comparator: Treatment Group E
    Day 0 Treatment / Formulation 2 Day 21 Treatment / Formulation 2
    Intervention: Biological: RSV F Vaccine with Aluminum Phosphate Adjuvant
  • Active Comparator: Treatment Group F
    Day 0 Treatment / Formulation 3 Day 21 Phosphate Buffer
    Interventions:
    • Biological: RSV F Vaccine
    • Biological: Matrix-M1 Adjuvant
    • Other: Phosphate Buffer
  • Active Comparator: Treatment Group G
    Day 0 Treatment / Formulation 3 Day 21 Treatment / Formulation 3
    Interventions:
    • Biological: RSV F Vaccine
    • Biological: Matrix-M1 Adjuvant
  • Active Comparator: Treatment Group H
    Day 0 Treatment / Formulation 4 Day 21 Phosphate Buffer
    Interventions:
    • Biological: RSV F Vaccine
    • Biological: Matrix-M1 Adjuvant
    • Other: Phosphate Buffer
  • Active Comparator: Treatment Group J
    Day 0 Treatment / Formulation 4 Day 21 Treatment / Formulation 4
    Interventions:
    • Biological: RSV F Vaccine
    • Biological: Matrix-M1 Adjuvant
  • Active Comparator: Treatment Group K
    Day 0 Treatment / Formulation 5 Day 21 Phosphate Buffer
    Interventions:
    • Biological: RSV F Vaccine
    • Biological: Matrix-M1 Adjuvant
    • Other: Phosphate Buffer
  • Active Comparator: Treatment Group L
    Day 0 Treatment / Formulation 5 Day 21 Treatment / Formulation 5
    Interventions:
    • Biological: RSV F Vaccine
    • Biological: Matrix-M1 Adjuvant
  • Placebo Comparator: Treatment Group M
    Day 0 Phosphate Buffer Day 21 Phosphate Buffer
    Intervention: Other: Phosphate Buffer
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
300
Same as current
July 2018
April 2017   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Males and females 60 through 80 years of age who are ambulatory and live in the community or in an assisted-living facility that provides minimal assistance, such that the subject is primarily responsible for self-care and activities of daily living. Subjects may have one or more chronic medical diagnoses, but should be clinically stable as assessed by:

    • Absence of changes in medical therapy within one month due to treatment failure or toxicity (dose adjustments of ongoing therapies for optimal effect, or replacements within a class of drugs due to convenience or cost, will be deemed acceptable),
    • Absence of medical events qualifying as SAEs within one month of the planned vaccination on Day 0, and
    • Absence of known, current, and life-limiting diagnoses which, in the opinion of the investigator, render survival to completion of the protocol unlikely.
  2. Willing and able (on both a physical and cognitive basis) to give informed consent prior to study enrollment. To complete the consent process, all qualifying subjects will correctly answer at least 4 out of 5 questions of the informed consent form (ICF) comprehension assessment in no more than 2 attempts.
  3. Able to comply with study requirements. As the protocol procedures involve telephone contacts for safety ascertainment, eligible subjects must have a reliable access to a telephone.

Exclusion Criteria:

  1. Received any prior RSV vaccine.
  2. Participation in research involving any additional investigational product (drug / biologic / device) within 45 days before planned date of first vaccination.
  3. History of a serious reaction to any prior vaccination or a history of Guillain-Barré syndrome (GBS) within 6 weeks of any prior influenza immunization.
  4. Receipt of inactivated influenza vaccine within 14 days prior to the Day 0 dose of test article or any other vaccine within the 4 weeks prior to the Day 0 dose of test article.
  5. Any known or suspected immunosuppressive condition, acquired or congenital, as determined by history and/or physical examination.
  6. Chronic administration (defined as more than 14 continuous days) of immunosuppressants or other immune-modifying drugs within 6 months prior to the administration of the study vaccine. An immunosuppressant dose of glucocorticoid will be defined as a systemic dose ≥ 10 mg of prednisone per day or equivalent. The use of topical, inhaled, and nasal glucocorticoids will be permitted.
  7. Administration of immunoglobulins and/or any blood products within the 3 months preceding the administration of the study vaccine or during the study.
  8. Acute disease at the time of enrollment (defined as the presence of a moderate or severe illness with or without fever, or an oral temperature ≥ 38.0°C on the planned day of vaccine administration).
  9. Known disturbance of coagulation. Potential subjects receiving aspirin, clopidogrel, prasugrel, dipyridamole, dabigatran, apixaban, rivaroxaban, or warfarin under good control for cardiovascular prophylaxis or prophylaxis of thromboembolic disease or stroke in the setting of atrial fibrillation will NOT be excluded.
  10. Suspicion or recent history (within one year of planned vaccination) of alcohol or other substance abuse.
  11. Any condition that in the opinion of the investigator would pose a health risk to the subject if enrolled or could interfere with evaluation of the vaccine or interpretation of study results (including neurologic, cognitive, or psychiatric conditions deemed likely to impair the quality of study compliance or safety reporting).
Sexes Eligible for Study: All
60 Years to 80 Years   (Adult, Older Adult)
Yes
Contact information is only displayed when the study is recruiting subjects
Australia
 
 
NCT03026348
RSV-E-205
No
Not Provided
Plan to Share IPD: Undecided
Novavax
Novavax
Not Provided
Study Director: Vivek Shinde, MD Novavax
Novavax
September 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP